Ultragenyx Pharmaceutical Inc. vs ImmunityBio, Inc.: SG&A Expense Trends

Biotech Giants' SG&A Expenses: A Decade of Change

__timestampImmunityBio, Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 2014432600010811000
Thursday, January 1, 201522620600033001000
Friday, January 1, 20169439100064936000
Sunday, January 1, 20175382100099909000
Monday, January 1, 201835463000127724000
Tuesday, January 1, 201946456000161524000
Wednesday, January 1, 202071318000182933000
Friday, January 1, 2021135256000219982000
Saturday, January 1, 2022102708000278139000
Sunday, January 1, 2023129620000309799000
Loading chart...

Unlocking the unknown

SG&A Expense Trends: Ultragenyx vs. ImmunityBio

In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Ultragenyx Pharmaceutical Inc. and ImmunityBio, Inc. over the past decade. From 2014 to 2023, Ultragenyx's SG&A expenses surged by approximately 186%, peaking in 2023. In contrast, ImmunityBio experienced a more volatile trajectory, with a significant spike in 2015, marking a 5,130% increase from the previous year. By 2023, ImmunityBio's expenses had stabilized, showing a 2,896% increase from 2014. These trends highlight the strategic financial maneuvers each company has undertaken to navigate the biotech sector's challenges. As the industry evolves, monitoring such financial metrics will be pivotal for stakeholders aiming to gauge company performance and strategic direction.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025